Medicamen Organics Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹35 Cr
Medicamen Organics targets revenues of INR 60-65 crores for FY '26. Medicamen Organics Limited targets **60% CAGR revenue growth** over the next three years.
From Medicamen Organics Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹24.3
Market Cap
₹35 Cr
Revenue Rank
Margin Rank
How does Medicamen Organics Ltd rank in Pharmaceuticals & Biotechnology?
Compare Medicamen Organics Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 1- →Medicamen Organics targets revenues of INR 60-65 crores for FY '26.
- →The company plans a 60% CAGR in revenue over the next three years.
- →Expansion includes a 20% capacity increase at the Haridwar facility.
- →Nepal facility expected to contribute from FY '27 onwards, with optimum potential above INR 400 crores.
- →Focus on growing export markets, aiming for 75% export and 25% domestic revenue mix.
- →Plans to register around 120 products in Africa over the next two years.
- →Growth driven by diversification into personal care/cosmetics with INR 15 crores revenue targeted for FY '26.
- →Expansion into better, more profitable markets like Latin America and Europe through associate manufacturing.
- →Anticipated rise in volumes supported by capacity additions and geographic market expansion.
📈 Profitability & Margins
Rank 3- →Medicamen Organics Limited targets **60% CAGR revenue growth** over the next three years.
- →For FY '26, projected revenue is around **INR 60-65 crores**.
- →EBITDA margins expected around **24%**, considering new segments like cosmetics and personal care.
- →Profit After Tax (PAT) aims to be maintained at or above **10%**.
- →Growth drivers include expansion into new markets such as East Africa, Nepal, and Europe, with 120 product registrations planned.
- →Margins are currently around 17%, expected to improve as marketing investments stabilize and focus shifts to profitable products.
- →Optimum utilization of existing capacity is 60-65%, with a planned **20% capacity expansion** to support growth.
- →Nepal facility to contribute significantly after commercialization, with potential revenues exceeding **INR 400 crores** at full optimal utilization.
- →EPS expected to improve in line with revenue and profitability growth, supported by internal accrual funding and no immediate dividend payout to reinvest in expansion.
🏗️ Capital Expenditure Plans
Yes- →INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
- →Expansion of Haridwar manufacturing facility by 20% underway to enhance operational efficiency and scale production.
- →Plans to construct an EU-approved manufacturing facility for better control over production, targeted commercialization starting around 15 months from now, with first-year revenue potential of INR50 crores.
- →No current plans for fundraising; expansions funded through internal accruals and INR3 crores raised via convertible warrants from Promoter Group.
- →The Nepal facility represents a strategic investment to enter new markets and meet European quality standards, supplementing capacity and global footprint.
- →Future plan includes possible manufacturing facility in Africa in 2-3 years to access new markets.
💰 Fundraising & Capital Structure
No- →Currently, Medicamen Organics Limited is funding all its expansion through internal accruals.
- →There are no immediate plans for generating funds through debt or equity.
- →The company has raised INR 3 crores via issuing and allotting 4,65,910 convertible warrants on a preferential basis to the Promoter Group to strengthen working capital without affecting the existing financial structure.
- →For the Nepal facility investment, the company plans to invest around INR 9 crores as its portion of capital, which will be funded internally.
- →No explicit mention of future fundraising through debt or equity was made; the focus remains on internal accrual funding and controlled investments.
📋 Order Book & Pipeline
No information- →Current orders in hand with the East Africa subsidiary stand at around $125,000.
- →An advance payment of $50,000 has been received from the subsidiary.
- →The first shipment from the East Africa operations is scheduled for this month.
- →Post initial shipment, similar subsequent orders are expected.
- →The company is preparing for a good influx of orders this year, supported by 20% capacity expansion at the primary facility.
- →Focus on markets like Latin America (Mexico, Brazil), Europe, and Francophone Africa is expected to drive order growth.
- →The company is also targeting registrations of around 120 products over the next two years, which should contribute significantly to revenues from FY '26 onwards.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Medicamen Organics Ltd Q4 FY25 results?
Medicamen Organics targets revenues of INR 60-65 crores for FY '26. Medicamen Organics Limited targets **60% CAGR revenue growth** over the next three years.
What is Medicamen Organics Ltd share price analysis?
Medicamen Organics Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹35 Cr. Investors should review the full earnings analysis for detailed insights.
Is Medicamen Organics Ltd planning capital expenditure?
INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
Keep Medicamen Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.